Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ayahuasca is a traditional South American psychoactive brew made primarily from the Banisteriopsis caapi vine and leaves of Psychotria viridis or other DMT-containing plants. The main active compounds are N,N-dimethyltryptamine (DMT), a potent serotonergic hallucinogen, and harmala alkaloids (harmine, harmaline, tetrahydroharmine) which act as reversible monoamine oxidase-A inhibitors (MAOIs). The MAOIs in B. caapi prevent rapid breakdown of orally ingested DMT by monoamine oxidase enzymes in the gut and liver, allowing DMT to become psychoactive when consumed orally. Ayahuasca produces profound alterations in consciousness including hallucinations and changes in perception due to agonism at serotonin receptors—primarily 5-HT2A—by both DMT and certain β-carbolines. Traditionally used for spiritual and religious purposes among Amazonian peoples, it is also being researched for potential therapeutic effects on depression and addiction[1][2][4][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ayahuasca.